Graefe's Archive for Clinical and Experimental Ophthalmology

, Volume 245, Issue 12, pp 1877–1880

Ranibizumab for retinal angiomatous proliferation in neovascular age-related macular degeneration

Authors

    • Department of Ophthalmology and Visual SciencesThe Chinese University of Hong Kong, Hong Kong Eye Hospital
  • Wai-Man Chan
    • Department of Ophthalmology and Visual SciencesThe Chinese University of Hong Kong, Hong Kong Eye Hospital
  • David T. Liu
    • Department of Ophthalmology and Visual SciencesThe Chinese University of Hong Kong, Hong Kong Eye Hospital
  • Dennis S. Lam
    • Department of Ophthalmology and Visual SciencesThe Chinese University of Hong Kong, Hong Kong Eye Hospital
Case Report

DOI: 10.1007/s00417-007-0679-1

Cite this article as:
Lai, T.Y.Y., Chan, W., Liu, D.T. et al. Graefes Arch Clin Exp Ophthalmol (2007) 245: 1877. doi:10.1007/s00417-007-0679-1

Abstract

Background

To report the efficacy of intravitreal injection of ranibizumab (Lucentis) in the treatment of retinal angiomatous proliferation (RAP) in neovascular age-related macular degeneration (AMD).

Methods

Case review of four consecutive patients who received 3 injections at monthly intervals of intravitreal ranibizumab injections for RAP. The serial changes in best-corrected visual acuity (BCVA), optical coherence tomography (OCT), fluorescein angiography (FA), and indocyanine green angiography (ICGA) are presented.

Results

The baseline mean logMAR BCVA was 0.89 (Snellen equivalent of 20/155). After three injections of ranibizumab, all four patients had visual improvement and the mean logMAR BCVA improved to 0.59 (Snellen equivalent of 20/78). The mean visual improvement was 3.0 lines. All patients also had complete resolution of subretinal fluid after treatment, and the mean OCT central foveal thickness reduced from 438 μm at baseline to 169 μm at 3 months. Follow-up FA and ICGA at 3 months showed absence of leakage in three patients with minimal leakage in the remaining patient. One patient had recurrence of RAP at 8 months after commencement of treatment, and repeat ranibizumab injection resulted in resolution of the subretinal fluid and pigment epithelial detachment and visual improvement.

Conclusions

Intravitreal ranibizumab injections appeared to be an effective treatment for RAP, resulting in visual gain and reduction in macular thickness. Further long-term studies to evaluate the efficacy of intravitreal ranibizumab in RAP are warranted.

Keywords

Retinal angiomatous proliferationAge-related macular degenerationRanibizumabAnti-VEGF

Copyright information

© Springer-Verlag 2007